Sponsored by:
Gary Krishnan, Eli Lilly, USA
Peter Lander, Eli Lilly, USA
Many companies have established platform approaches to identify novel leads and drug candidates for protein families or classes such as GPCRs, enzymes and ion channels. These efforts have addressed target biology and screening and have presented exciting opportunities to address therapeutic opportunities. These platform approaches have enabled high-throughput assays that optimally address target biology and selectivity and seize synergies among the individual projects in the same target class. This session will focus on the application of novel and traditional approaches used to produce better leads and candidates that target the biology of these important target classes.